The benefit of PARP inhibitors varied significantly based on the tumor's molecular profile, particularly its homologous recombination repair capability. While patients with deficiencies in this ...
SAN FRANCISCO -- Patients with colon cancer and comorbid obesity treated with GLP-1 receptor agonists had lower mortality and ...
Georgetown University's Lombardi Comprehensive Cancer Center researchers have identified a new way to reprogram T cells, ...
Run by Roger Perlmutter and backed by more than $1 billion in private funding, Eikon will use the IPO proceeds to advance a ...
Researchers have identified a new way to reprogram T cells, which are infection and tumor-fighting white blood cells, so that they have a superior memory, thereby making them more effective in killing ...
Fast Track designation granted by U.S. FDA for evaluation of ETX-19477 in patients with BRCA-mutated, platinum-resistant ...
The approval is supported by the pivotal TRITON3 Phase 3 trial, which demonstrated that Rubraca is the first and only PARP inhibitor to exceed the efficacy of docetaxel in a direct, head-to-head ...
NEW YORK – The US Food and Drug Administration on Wednesday granted full approval to Pharma&'s PARP inhibitor Rubraca (rucaparib) for previously treated patients with metastatic castration-resistant ...
Rucaparib is now approved for BRCA mutation-associated mCRPC patients post-androgen receptor therapy, without prior chemotherapy requirement. The TRITON3 trial showed significant improvement in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback